AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30079331 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (score ≤2, no or low damage)
Number of subjects: 120
Study 30079331 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (score >2, high damage)
Number of subjects: 120
Study 30079331 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 120
Study 30079388 — intervention group
Group type: EXPERIMENTAL
Intervention: High tie ligation
Number of subjects: 331
Study 30079388 — intervention group
Group type: COMPARATOR
Intervention: Low tie ligation
Number of subjects: 331
Study 30079464 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous laryngeal ultrasound (TCLUS) pre- and post-operatively
Number of subjects: 100
Study 30079464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment of TCLUS, subjective evaluation, and VFDV
Number of subjects: 100
Study 30079464 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective assessment of VF mobility
Number of subjects: 100
Study 30079464 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal fold displacement velocity (VFDV) estimation
Number of subjects: 100
Study 30079582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) drug levels < 200 ng/ml or undetectable desethylchloroquine
Number of subjects: 305
Study 30079582 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires (MASRI < 80%)
Number of subjects: 305
Study 30079582 — intervention group
Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 305
Study 30080739 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 200
Study 30080739 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of the primary tumor
Number of subjects: 200
Study 30080739 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CTCs subpopulations
Number of subjects: 200
Study 30080739 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment score based on tCTCs increase
Number of subjects: 200
Study 30081223 — intervention group
Group type: EXPERIMENTAL
Intervention: EG Scan II (transnasal capsule endoscope)
Number of subjects: 200
Study 30081223 — intervention group
Group type: COMPARATOR
Intervention: C-EGD (conventional esophagogastroduodenoscopy)
Number of subjects: 200
Study 30081838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing treatment with zidovudine (76% of children, median duration 48 months (26-74))
Number of subjects: 254
Study 30081838 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous treatment with stavudine (18% of children, median treatment duration 8 months (5-25))
Number of subjects: 254
Study 30081838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing treatment with lopinavir/ritonavir (27% of children, median duration 49 months (23-59))
Number of subjects: 254
Study 30081838 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys vs. girls
Number of subjects: 254
Study 30081845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit for Dialysis film
Number of subjects: 30
Study 30081846 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid administered prior to specialist consultation
Number of subjects: 0
Study 30081846 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid administered within the consultation
Number of subjects: 0
Study 30081846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both decision aids
Number of subjects: 0
Study 30081846 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30081857 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota and stool short chain fatty acids (SCFAs) measurement
Number of subjects: 2500
Study 30081857 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual measures of obesity risk factors (body composition, physical activity, dietary intake)
Number of subjects: 2500
Study 30081858 — intervention group
Group type: EXPERIMENTAL
Intervention: Women approached following a stillbirth (case)
Number of subjects: 12
Study 30081858 — intervention group
Group type: COMPARATOR
Intervention: Women approached during pregnancy (control)
Number of subjects: 12
Study 30081865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant HAI oxaliplatin plus systemic LV5FU2
Number of subjects: 114
Study 30081865 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic FOLFOX
Number of subjects: 114
Study 30081867 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 135 mg/day
Number of subjects: 13
Study 30081867 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 90 mg/day
Number of subjects: 13
Study 30081867 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib (both doses)
Number of subjects: 13
Study 30081867 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 13
Study 30081933 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE CHF-PC plus usual heart failure care
Number of subjects: 0
Study 30081933 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 30081937 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological resilience measured by the Connor-Davidson Resilience scale (CD-RISC)
Number of subjects: 0
Study 30081937 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by SF-36
Number of subjects: 0
Study 30081937 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Number of subjects: 0
Study 30081937 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of smoking, exercise habits, BMI, trust in treatment, and satisfaction with care
Number of subjects: 0
Study 30081967 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG) intervention delivered by trained family peers
Number of subjects: 3000
Study 30081967 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG) intervention delivered by community health workers
Number of subjects: 3000
Study 30081967 — intervention group
Group type: COMPARATOR
Intervention: Usual care comprising mental health care support materials and school support materials
Number of subjects: 3000
Study 30082172 — intervention group
Group type: EXPERIMENTAL
Intervention: Excellent glycemic control (mean HbA1c <7.2%)
Number of subjects: 240
Study 30082172 — intervention group
Group type: COMPARATOR
Intervention: Poor glycemic control (mean HbA1c >8.8%)
Number of subjects: 240
Study 30082340 — intervention group
Group type: EXPERIMENTAL
Intervention: SH003 (1 to 4 tablets, three times a day for 3 weeks)
Number of subjects: 6
Study 30082340 — intervention group
Group type: EXPERIMENTAL
Intervention: SH003 (dose escalation)
Number of subjects: 6
Study 30082349 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol syrup
Number of subjects: 236
Study 30082349 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol syrup (control)
Number of subjects: 236
Study 30082361 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteers assisting patients during weekday lunchtime and evening meals
Number of subjects: 65
Study 30082361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-saving aspect of the intervention
Number of subjects: 65
Study 30082366 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF core set identification through systematic review, qualitative interviews, online surveys, and cross-sectional study.
Number of subjects: 0
Study 30082367 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping Healthy Minds - a modular transdiagnostic intervention for mood, stressor-related and anxiety disorders
Number of subjects: 0
Study 30082367 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30082474 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 0
Study 30082474 — intervention group
Group type: COMPARATOR
Intervention: Single-agent options
Number of subjects: 0
Study 30082475 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg b.i.d. plus rituximab 375 mg/m2
Number of subjects: 45
Study 30082475 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 40 mg b.i.d. plus rituximab and vincristine
Number of subjects: 45
Study 30082489 — intervention group
Group type: EXPERIMENTAL
Intervention: High HI-T (>1.9) and high MAX-T (>10.5)
Number of subjects: 42
Study 30083405 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected obstructive sleep apnea (OSA) patients
Number of subjects: 10000
Study 30083405 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment modality and compliance
Number of subjects: 10000
Study 30083748 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir-grazoprevir on posttransplant day 3
Number of subjects: 20
Study 30084702 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study 30084880 — intervention group
Group type: EXPERIMENTAL
Intervention: MonAmour test
Number of subjects: 91
Study 30084880 — intervention group
Group type: COMPARATOR
Intervention: Reference standard tests (Bells test, Apples test, Neglect subtest of the Test for Attentional Performance)
Number of subjects: 91
Study 30084943 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 4 weeks (PK2)
Number of subjects: 26
Study 30084943 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 12 weeks (PK3)
Number of subjects: 26
Study 30084943 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 400 mg (EFV400) without coadministration (PK1)
Number of subjects: 26
Study 30085018 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for AF detection (5 min analysis)
Number of subjects: 592
Study 30085018 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for AF detection (1 min analysis)
Number of subjects: 592
Study 30085018 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for AF detection (5 min analysis with good signal quality)
Number of subjects: 592
Study 30085139 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose schedule of bivalent HPV vaccine (bHPV)
Number of subjects: 1629
Study 30085139 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of either bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine (qHPV)
Number of subjects: 1629
Study 30085139 — intervention group
Group type: COMPARATOR
Intervention: 3-dose schedule of bivalent HPV vaccine (bHPV)
Number of subjects: 1629
Study 30085409 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST PLUS test
Number of subjects: 435
Study 30086261 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-bowel capsule endoscopy (CE)
Number of subjects: 74
Study 30086408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 128
Study 30086408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 128
Study 30086649 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein intake diet
Number of subjects: 25
Study 30086649 — intervention group
Group type: COMPARATOR
Intervention: Standard protein intake diet
Number of subjects: 25
Study 30086682 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased trigeminal nerve volume in primary trigeminal neuralgia patients
Number of subjects: 80
Study 30086682 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced grey matter volume in primary trigeminal neuralgia patients
Number of subjects: 80
Study 30086682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis of trigeminal nerve volume and pain ratings
Number of subjects: 80
Study 30086729 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric model combining host and pathogen data for distinguishing between bacterial and viral infections.
Number of subjects: 1200
Study 30086729 — intervention group
Group type: EXPERIMENTAL
Intervention: New host- or pathogen-related biomarkers used to generate a multi-parametric model.
Number of subjects: 1200
Study 30086777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg BID, with incremental increases of 5 mg BID at weeks 12 and 18 (maximum 20 mg BID)
Number of subjects: 45
Study 30086774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 180
Study 30086774 — intervention group
Group type: COMPARATOR
Intervention: Cyanoacrylate adhesive (CAE)
Number of subjects: 180
Study 30086778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support system (EDSS) used by trained nurse care coordinators (NCCs) with regular SMSs to patients for 12 months
Number of subjects: 1876
Study 30086778 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm (paper-based hypertension treatment guidelines)
Number of subjects: 1876
Study 30086778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support system (EDSS) used by trained nurse care coordinators (NCCs)
Number of subjects: 1876
Study 30086783 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 118
Study 30086783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score including diabetes, hemoglobin and ECV > 33%
Number of subjects: 118
Study 30086783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiles of the probability score
Number of subjects: 118
Study 30087028 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib 150 mg twice daily combined with trametinib 1.0 mg once daily
Number of subjects: 21
Study 30087093 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring of blood pressure (TELEM) group
Number of subjects: 231
Study 30087093 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring by text message (TELEMEV) group
Number of subjects: 231
Study 30087093 — intervention group
Group type: EXPERIMENTAL
Intervention: TELEM-TELEMEV group
Number of subjects: 231
Study 30087093 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical treatment (UCT) group
Number of subjects: 231
Study 30087197 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication availability in the home
Number of subjects: 288
Study 30087197 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication readiness criteria
Number of subjects: 288
Study 30087197 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller medication availability in the home
Number of subjects: 288
Study 30087197 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller medication readiness criteria
Number of subjects: 288
Study 30087197 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about medications
Number of subjects: 288
Study 30087626 — intervention group
Group type: COMPARATOR
Intervention: Translocator Protein Density measurement
Number of subjects: 0
Study 30087850 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of chemotherapy
Number of subjects: 40
Study 30088048 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 20 mg/day with Carboplatin AUC6 (A/C)
Number of subjects: 38
Study 30088048 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day with Carboplatin AUC6 (A/C)
Number of subjects: 38
Study 30088048 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 20 mg/day with Carboplatin AUC6 and Paclitaxel 175 mg/m2 (A/C/P)
Number of subjects: 38
Study 30088146 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS total score for women
Number of subjects: 1379
Study 30088146 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS total score for men
Number of subjects: 1379
Study 30088146 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS negative score and PANSS affective score in women
Number of subjects: 1379
Study 30088146 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS positive score and PANSS affective score in men
Number of subjects: 1379
Study 30088146 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS affective score in women
Number of subjects: 1379
Study 30088146 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS affective, positive, and cognitive scores in men
Number of subjects: 1379
Study 30088146 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL reported by men
Number of subjects: 1379
Study 30088161 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCF plus trastuzumab
Number of subjects: 26
Study 30088178 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 16
Study 30088178 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 16
Study 30088198 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-based recombinant vaccine administered every 8 weeks for 48 weeks (seven doses)
Number of subjects: 20
Study 30088198 — intervention group
Group type: COMPARATOR
Intervention: Age-, gender-, and baseline HBsAg-matched control group
Number of subjects: 20
Study 30088336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) 3.4 MJ/810 kcal daily for 8 weeks
Number of subjects: 2224
Study 30088802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing measurements before and after inhaled albuterol (1 week before anticipated hospital discharge)
Number of subjects: 765
Study 30088802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing measurements in PROP infants with BPD
Number of subjects: 765
Study 30088802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing measurements in PROP infants with respiratory disease
Number of subjects: 765
Study 30088802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator response
Number of subjects: 765
Study 30088802 — intervention group
Group type: COMPARATOR
Intervention: Comparison with term infants
Number of subjects: 765
Study 30089118 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic clinical prediction rule (CPR) combined with AKI e-alert
Number of subjects: 30295
Study 30089118 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30295
Study 30089160 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 3 months
Number of subjects: 150
Study 30089160 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 30089406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium <20 mmol/L
Number of subjects: 200
Study 30089406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium >20 mmol/L
Number of subjects: 200
Study 30089406 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breastfed infants
Number of subjects: 200
Study 30089457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-fractionated radiotherapy at 40.0 Gy/2.5 Gy with concurrent S-1 at 80 mg/m2
Number of subjects: 9
Study 30089457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-fractionated radiotherapy
Number of subjects: 9
Study 30089523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication use review
Number of subjects: 900
Study 30089568 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR) monitoring
Number of subjects: 71
Study 30089568 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR monitoring
Number of subjects: 71
Study 30089664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 68
Study 30089716 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors≥5
Number of subjects: 75
Study 30089716 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors<5
Number of subjects: 75
Study 30089716 — intervention group
Group type: COMPARATOR
Intervention: aAb- relatives
Number of subjects: 75
Study 30091085 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 87
Study 30091207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) therapy followed by Non-Ablative Fractionated Laser (NAFL) treatment
Number of subjects: 30
Study 30091209 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to Healthy Nordic Food Index (HNFI)
Number of subjects: 2019
Study 30091209 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium adherence to Healthy Nordic Food Index (HNFI)
Number of subjects: 2019
Study 30091209 — intervention group
Group type: COMPARATOR
Intervention: Low adherence to Healthy Nordic Food Index (HNFI)
Number of subjects: 2019
Study 30091600 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTX660 (1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one)
Number of subjects: 0
Study 30092621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh reinforcement
Number of subjects: 4679
Study 30092621 — intervention group
Group type: COMPARATOR
Intervention: Non-mesh controls
Number of subjects: 4679
Study 30092840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cells (MSCs) and biphasic calcium phosphate granules as scaffolds
Number of subjects: 11
Study 30092840 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 11
Study 30092843 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus complete mesogastrium excision (D2 + CME)
Number of subjects: 336
Study 30092843 — intervention group
Group type: COMPARATOR
Intervention: Conventional D2 lymphadenectomy
Number of subjects: 336
Study 30092965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline therapy (Doxorubicin)
Number of subjects: 27
Study 30093048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR (Coronary Flow Reserve)
Number of subjects: 519
Study 30093048 — intervention group
Group type: COMPARATOR
Intervention: High CFR
Number of subjects: 519
Study 30093048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR among patients with high FFR (Fractional Flow Reserve)
Number of subjects: 519
Study 30093048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FFR and low CFR
Number of subjects: 519
Study 30093048 — intervention group
Group type: COMPARATOR
Intervention: High FFR
Number of subjects: 519
Study 30093147 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm Human Milk (PT HM)
Number of subjects: 500
Study 30093147 — intervention group
Group type: COMPARATOR
Intervention: Term Human Milk (T HM)
Number of subjects: 500
Study 30093147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PT HM and T HM
Number of subjects: 500